Skip to main content

Table 1 Clinical data and risk factors for the exhaled nitric oxide categories

From: Clinical patterns in asthma based on proximal and distal airway nitric oxide categories

 

All

asthmatics

(n = 179)

Non-asthmatic

(n = 21)

Type I

Normal Nitric Oxide

(n = 67)

Type II

Proximal Airway Predominant

(n = 66)

Type III

Proximal and Distal Airway Predominant

(n = 27)

Type IV

Distal Airway Predominant

(n = 19)

Overall test

p-value#

Paired comparison result$

DEMOGRAPHICS

Age

10

(6-17)

10

(6-17)

10

(6-17)

11

(6-17)

11

(6-16)

11

(6-17)

0.13

-----

Gender

Male

117

(65%)

12

(57%)

48

(72%)

44

(67%)

16

(59%)

9

(47%)

0.30

-----

Atopy

143

(80%)

0

(0%)

44

(66%)

62

(94%)

23

(89%)

12

(63%)

0.0001

II>I, IV

ICS

treatment

110

(61%)

-----

53

(79%)

37

(56%)

5

(18%)

15

(79%)

<0.0001

III<I, II, IV

II<I

EXHALED NITRIC OXIDE

FENO,50

19.6

(3.7-186)

8.5

(2.2-15.3)

9.4

(3.7-18.4)

33.4

(17.7-186)

49.9

(22.3-159)

8.5

(4.6-16.9)

0.0001

II, III>NC, I, IV

III>II

J'awNO (nl/s)

1.6

(0.1-17)

0.7

(0.1-1.4)

0.7

(0.1-1.5)

3.0

(1.6-17)

3.5

(1.5-13.7)

0.5

(0.1-1.3)

0.0001

II, III>NC, I, IV

CANO (ppb)

1.3

(0.1-13.4)

1.5

(0.1-2.2)

1.0

(0.006-2.3)

0.8

(0.02-2.2)

3.8

(2.4-13.4)

3.1

(2.3-5.1)

0.0001

III, IV>NC, I, II

III>IV

CONTROL and MORBIDITY

FEV1/FVC

87.0

(70.4-102.1)

89.6

(84.5-102.1)

89.4

(71.7-100)

85.5

(70.4-101)

83.3

(72-100.1)

87.8

(80.7-100.7)

0.0016

III<I, NC

FEV1 (%)

106

(67.1-149)

106

(92.6-118)

108

(75.1-149)

105

(67.1-149)

106

(76.2-132)

103

(77.9-127)

0.68

-----

BDR

6.3

(0-35.5)

[n = 167]

5.3

(0.6-6.6)

[n = 13]

4.1

(0-13.8)

[n = 63]

7.0

(0-27.4)

[n = 60]

10.1

(0.7-35.5)

[n = 26]

5.0

(0.7-10.6)

[n = 18]

<0.0001

II>I

III>NC, I, IV

ACT

21

(10-27)

-----

23

(17-27)

22

(17-26)

17

(10-23)

17

(10-24)

<0.0001

III, IV<I, II

Morbidity*

26

(15%)

-----

8

(12%)

3

(4.5%)

9

(33%)

6

(32%)

<0.0001

III, IV>II

  1. Data is presented as median (minimum-maximum) or number of subjects (proportion). NC, non-asthmatic control; ICS, inhaled corticosteroid; ACT, Asthma Control Test; BDR, bronchodilator response;
  2. * Number of subjects with at least one event in the past 8 weeks including visits to the emergency department, severe attacks, and hospitalizations.
  3. #Mantel-Haenszel chi-square test for Gender, Atopy, ICS treatment and Morbidity; and Kruskal-Wallis test for all other variables. Comparisons made between non-asthmatic control and Type I-IV categories
  4. $Bonferroni's multiple comparison adjustment was applied for paired comparison.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us